Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL
Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis
Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival
Gabapentin plus tramadol reduces opioid escalation for mucositis pain in head & neck cancer
Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy
Understanding patient expectations and clinicians' goals in favourable risk aRCC patients